Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T-cell Therapy
Overview
Authors
Affiliations
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult patients with B-ALL progress after CD19 CAR T-cell therapy. Data on the natural history, management, and outcome of adult B-ALL progressing after CD19 CAR T cells have not been described in detail. Herein, we report comprehensive data of 38 adult patients with B-ALL who progressed after CD19 CAR T therapy at our institution. The median time to progression after CAR T-cell therapy was 5.5 months. Median survival after post-CAR T progression was 7.5 months. A high disease burden at the time of CAR T-cell infusion was significantly associated with risk of post-CAR T progression. Thirty patients (79%) received salvage treatment of post-CAR T disease progression, and 13 patients (43%) achieved complete remission (CR), but remission duration was short. Notably, 7 (58.3%) of 12 patients achieved CR after blinatumomab and/or inotuzumab administered following post-CAR T failure. Multivariate analysis revealed that a longer remission duration from CAR T cells was associated with superior survival after progression following CAR T-cell therapy. In summary, overall prognosis of adult B-ALL patients progressing after CD19 CAR T cells was poor, although a subset of patients achieved sustained remissions to salvage treatments, including blinatumomab, inotuzumab, and reinfusion of CAR T cells. Novel therapeutic strategies are needed to reduce risk of progression after CAR T-cell therapy and improve outcomes of these patients.
Zhu J, Zhou J, Liang X, An F, Ding Y, Jiao X BMC Med. 2025; 23(1):138.
PMID: 40038688 PMC: 11881286. DOI: 10.1186/s12916-025-03968-5.
Yang T, Dong Y, Zhang M, Feng J, Fu S, Xiao P Exp Hematol Oncol. 2025; 14(1):2.
PMID: 39754190 PMC: 11697943. DOI: 10.1186/s40164-024-00593-5.
Friedes B, DiNofia A, Iannone E, Li Y, Rheingold S, Leahy A Blood Adv. 2024; 9(2):354-359.
PMID: 39565957 PMC: 11787456. DOI: 10.1182/bloodadvances.2024014518.
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.
Wang Y, Xue Y, Zuo Y, Jia Y, Lu A, Zeng H J Transl Med. 2024; 22(1):680.
PMID: 39061064 PMC: 11282679. DOI: 10.1186/s12967-024-05362-w.
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.
Dreyzin A, Rankin A, Luciani K, Gavrilova T, Shah N Expert Rev Clin Immunol. 2024; 20(7):745-763.
PMID: 38739466 PMC: 11180598. DOI: 10.1080/1744666X.2024.2349738.